dc.contributor.author	Dodgen, Tyren M.
dc.contributor.author	Hochfeld, Warren E.
dc.contributor.author	Fickl, Heidi
dc.contributor.author	Asfaha, Sahle M.
dc.contributor.author	Durandt, Chrisna
dc.contributor.author	Rheeder, Paul
dc.contributor.author	Drogemoller, Britt I.
dc.contributor.author	Wright, Galen E. B.
dc.contributor.author	Warnich, Louise
dc.contributor.author	Labuschagne, Christiaan D. J.
dc.contributor.author	Van Schalkwyk, Antoinette
dc.contributor.author	Gaedigk, Andrea
dc.contributor.author	Pepper, Michael S.
dc.date.accessioned	2013-06-26T13:59:53Z
dc.date.available	2013-06-26T13:59:53Z
dc.date.issued	2013-01
dc.date.updated	2013-03-24T07:03:27Z
dc.description	The original publication is available at http://www.biomedcentral.com/1471-2350/14/20	en_ZA
dc.description.abstract	Abstract Background Adverse drug reactions and lack of therapeutic efficacy associated with currently prescribed pharmacotherapeutics may be attributed, in part, to inter-individual variability in drug metabolism. Studies on the pharmacogenetics of Cytochrome P450 (CYP) enzymes offer insight into this variability. The objective of this study was to compare the AmpliChip CYP450 Test® (AmpliChip) to alternative genotyping platforms for phenotype prediction of CYP2C19 and CYP2D6 in a representative cohort of the South African population. Methods AmpliChip was used to screen for thirty-three CYP2D6 and three CYP2C19 alleles in two different cohorts. As a comparison cohort 2 was then genotyped using a CYP2D6 specific long range PCR with sequencing (CYP2D6 XL-PCR + Sequencing) platform and a PCR-RFLP platform for seven CYP2C19 alleles. Results Even though there was a low success rate for the AmpliChip, allele frequencies for both CYP2D6 and CYP2C19 were very similar between the two different cohorts. The CYP2D6 XL-PCR + Sequencing platform detected CYP2D65 more reliably and could correctly distinguish between CYP2D62 and 41 in the Black African individuals. Alleles not covered by the AmpliChip were identified and four novel CYP2D6 alleles were also detected. CYP2C19 PCR-RFLP identified CYP2C199,15, 17 and 27 in the Black African individuals, with 2, 17 and 27 being relatively frequent in the cohort. Eliminating mismatches and identifying additional alleles will contribute to improving phenotype prediction for both enzymes. Phenotype prediction differed between platforms for both genes. Conclusion Comprehensive genotyping of CYP2D6 and CYP2C19 with the platforms used in this study, would be more appropriate than AmpliChip for phenotypic prediction in the South African population. Pharmacogenetically important novel alleles may remain undiscovered when using assays that are designed according to Caucasian specific variation, unless alternate strategies are utilised.	en_ZA
dc.description.version	Publishers' Version	en_ZA
dc.format.extent	15 p. : ill.
dc.identifier.citation	Dodgen, T. M. et al. 2013. Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study.BMC Medical Genetics, 14(1):20, doi:10.1186/1471-2350-14-20.	en_ZA
dc.identifier.issn	1471-2350 (online)
dc.identifier.other	doi.org/10.1186/1471-2350-14-20
dc.identifier.uri	http://hdl.handle.net/10019.1/80949
dc.language.iso	en_ZA	en_ZA
dc.language.rfc3066	en_ZA
dc.publisher	BioMed Central	en_ZA
dc.rights.holder	Tyren M Dodgen et al.; licensee BioMed Central Ltd.	en_ZA
dc.subject	Pharmacogenetics	en_ZA
dc.subject	Cytochrome P-450 enzymes	en_ZA
dc.title	Introduction of the AmpliChip CYP450 Test to a South African cohort : a platform comparative prospective cohort study	en_ZA
dc.type	Article	en_ZA

Introduction of the AmpliChip CYP450 Test to a South African cohort : a platform comparative prospective cohort study

Files

Original bundle

License bundle

Collections